GENNADIY GOLDVEKHT: Open Payments
NPI 1093212086 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,886 in 90 payments from 12 companies in 2025. Trend: 2023 $1,240 · 2024 $2,048 · 2025 $2,886
Food & beverage: $2,884Education: $2
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $964 |
| Lundbeck LLC | 16 | $431 |
| Alkermes, Inc. | 8 | $306 |
| Axsome Therapeutics, Inc. | 6 | $264 |
| Vanda Pharmaceuticals Inc. | 11 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $201 |
| Neurocrine BioSciences, Inc. | 5 | $145 |
| E.R. Squibb & Sons, L.L.C. | 3 | $107 |
| ABBVIE INC. | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $74 |
Products named: REXULTI, LYBALVI, Auvelity, FANAPT, TRINTELLIX, INGREZZA, ABILIFY ASIMTUFII, COBENFY.
Industry payments across NY — which companies pay providers there.
